Michelutti A, Michieli M, Damiani D, Melli C, Geromin A, Russo D, Fanin R, Baccarani M
Department of Morphologic and Clinical Research, Udine University School of Medicine, Italy.
Haematologica. 1994 May-Jun;79(3):200-4.
Philadelphia (Ph) positive chronic myeloid leukemia (CML) cannot be induced into a true remission with conventional chemotherapy. Blast cells and precursors obtained from 51 Ph+ CML cases were assayed for expression of the multidrug resistance (MDR)-associated glycoprotein (p170) by immunocytochemistry (APAAP) with the MRK-16 monoclonal antibody.
Positive cells were found in 11/17 cases in chronic phase (65%), in 4/8 cases in accelerated phase, and in 23/26 cases in blastic phase (89%). The proportion of positive cells, which ranged between less than 1% and 95%, was higher in blastic phase (mean 32 +/- 29.9) than in chronic phase (mean 3 +/- 5.3) (p = 0.006). These findings show that p170 overexpression is common in Ph+ CML, especially after progression to blastic phase, and suggest that p170-related MDR may contribute significantly to treatment failure.
费城（Ph）阳性慢性髓性白血病（CML）无法通过传统化疗诱导至真正缓解。采用MRK - 16单克隆抗体，通过免疫细胞化学法（APAAP）对51例Ph + CML病例的原始细胞和前体细胞进行多药耐药（MDR）相关糖蛋白（p170）表达检测。
慢性期17例中有11例（65%）检测到阳性细胞，加速期8例中有4例，急变期26例中有23例（89%）。阳性细胞比例在1%以下至95%之间，急变期（平均32±29.9）高于慢性期（平均3±5.3）（p = 0.006）。这些发现表明，p170过表达在Ph + CML中常见，尤其是进展至急变期后，提示p170相关的多药耐药可能是治疗失败的重要原因。
